Download

Download Full Text (422 KB)

Contents

  • New Drugs for Myeloproliferative Neoplasms Ease Suffering and Extend Life: A new class of drugs has redefined treatment for patients with myeloproliferative neoplasms by easing their symptom burden while extending their lives
  • Neoadjuvant Targeted Therapy May Offer Multiple Benefits for Patients with Locally Advanced Renal Cancer: Despite definitive treatment with nephrectomy, locally advanced renal cancer recurs in 20%-30% of patients, substantially reducing their chance for long-term survival. To prevent such recurrences and prolong survival, urologic oncologists are studying the integration of targeted molecular therapies with surgical treatments
  • New Combination Therapy Offers Potential to Cure FLT3-ITD Acute Myelogenous Leukemia: A new combination therapy using plerixafor, granulocyte colony-stimulating factor (G-CSF), and sorafenib may lead to lasting remissions-and possibly even a cure-for patients with acute myelogenous leukemia (AML) carrying the internal tandem duplication (ITD) mutation in the Fms-like tyrosine kinase 3 (FLT3) gene
  • HOUSE CALL: Symptoms of Cancer-Lasting symptoms can mean cancer or other diseases

Publication Date

10-1-2014

Publisher

The University of Texas MD Anderson Cancer Center

City

Houston, Texas

Keywords

Verstovsek, Srdan; Wood, Christopher; Karam, Jose; Andreeff, Michael, 1943-; Myeloproliferative Disorders; Leukemia; Janus Kinase 2; Polycythemia Vera; Thrombocytosis; Clinical Trials as Topic; Molecular Targeted Therapy; Neoadjuvant Therapy; Kidney Neoplasms; Nephrectomy; Surgical Procedures, Operative; Leukemia, Myeloid, Acute; fms-Like Tyrosine Kinase 3; Neoplasms -- diagnosis.

Disciplines

History of Science, Technology, and Medicine | Oncology

Conditions Governing Access

Open

OncoLog, Volume 59, Number 10, October 2014

Share

COinS